Amarin Corp Plc (AMRN)

[rafunrafun]

IF (and that is a very big IF) you have any personal experience with this, unless you ran a RI-like trial, it is literally impossible for you to comment on Vascepa's effectiveness.

The fact that vascepa reduces multiple biomarkers for Marine & Anchor populations, is indisputable; that is proven by nearly 1,000 enrollees in those two trials. Again, TG was reduced by 33% and 22%, respectively, and so were many other biomarkers.

So based on the above paragraph, we have established that you cannot refute that vascepa reduces multiple biomarkers. The only other possibility left for explaining your statement about vascepa not being effective is that it does not reduce cardiovascular events. However, how on Earth could you possibly know that?! If a handful (and I mean a very small handful) of your so-called patients experienced CV events after taking vascepa, IS THAT YOUR PROOF OF ITS INEFFECTIVENESS?

If so, you surely must have the numbers - how many had events? How many did not? How long were they on vascepa? How many patients not on vascepa had events?

Without such data (WHICH TOT DO NOT HAVE) it is literally impossible for you to comment on effectiveness of vascepa.

Substance over philosophy, please.